Previous Close | 15.80 |
Open | 16.32 |
Bid | 0.00 x 1300 |
Ask | 0.00 x 2200 |
Day's Range | 11.99 - 17.41 |
52 Week Range | 8.72 - 30.43 |
Volume | |
Avg. Volume | 86,127 |
Market Cap | 624.25M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.28 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 46.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for GHRS
DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2022 and gave updates on its business. First Quarter 2022 Financial Highlights Cash position Cash was $270.8 million as of March 31, 2022, compared to $276.8 million as of December 31, 2021. We believe that our existing c
DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2021 and gave updates on its business. Fourth Quarter 2021 Business Highlights In December 2021, we reported the successful outcome of the Phase 2 part of our Phase 1/2 clinical trial of GH001, our proprietary inhalable
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...